A virus-like particulate vaccine (VLP) developed by Turkish scientists against the coronavirus has started new trials. The developers will recruit 600 volunteers for a new phase in the vaccine approved by the Turkey COVID-19 platform of the state-run Scientific and Technological Research Council of Turkey (TUBITAK).
Scientists hope add inside the country developed vaccines against the deadly infection, after Turkovac, which recently became the first local jab approved in Turkey.
Teams led by professor couple Mayda Gürsel and Ihsan Gürsel, respectively from the University technique of the Middle East (METU) and Bilkent University, two universities based in the Turkish capital Ankara, are behind the development of the vaccine. Nobel Ilaç, a local pharmaceutical company, will mass-produce the jab.
The trials of phase 1 and from phase 2 of the vaccine are completed with 376 volunteers. It has now started trials of phase 2-B, which will include volunteers who have been vaccinated with other blows. the new phase to compare to son efficacy compared to messenger RNA (mRNA) vaccine in a randomized, parallel-dose trial.
Vaccinated volunteers with two doses of Pfizer-BioNTech’s mRNA vaccine sooner will be eligible for the trial. Half of volunteers will be administered one dose of the mRNA vaccine, while the others will be administered one dose of the VLP shot.
TÜBITAK said in A declaration on Tuesday that the “innovative” vaccine had the ability to be adapted for combat against different variants of the coronavirus. The statement said earlier trials indicated the vaccine was safe, had high efficacy and was “tolerated” by the body. He said the trials would be held in at least three centers in Turkey and were an important step in the licensing process of the vaccine as the “only one in the world with four antigens.
After the omicron variant took hold in the country and drove up the number of daily cases at more over 100,000, Turkey has managed to contain the pandemic significantly. On Monday, it reported just 24,404 new cases and 133 deaths. The omicron variant reduced hospitalizations and need for intensive care for most patients, experts say. In light of the improvement in the state of pandemic, Turkey recently eased restrictions, including son outdoor mask rule.
Vaccination and mass immunity are essential for the country to overcome the pandemic, which made son foray into Turkey in March 2020. Since vaccination program started in January 2021, more over 146 millions doses were administered to the Turks public. The number of people with two doses of vaccine exceeded 52 millions. But experts say third or more the blows are required to protect the population, citing that senior citizens and people with chronic diseases always have a high risk of infection, even with micron. More than 27.4 millions people have been administered third injections so far.
